On this week’s Few & Far Between podcast episode, Biorasi’s CEO, Chris O'Brien, welcomes Karen Petrou and David Brint for an in-depth discussion on BioBonds and how they can jumpstart funding in clinical research for rare disease and other disorders.
"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...
How do you obtain the best possible patient care available? On this week's Few & Far Between podcast, host Chris O'Brien welcomes patient advocacy...
How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan...